6.99
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kintara Therapeutics Inc | KTRA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.99 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 3.5022 - 42.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 6.99 | USD |
Kintara Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 11.30M | 1.62M | 1.61M | $ - | $ - | -27.50 | -0.30 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 4.48M | 3.50% |
Kintara Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KTRA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.70 | 7.65 | 5.91 | 6.44 | 27,970 | 0.29 | 4.33% |
1 Month | 8.01 | 8.4777 | 5.59 | 6.86 | 31,020 | -1.02 | -12.73% |
3 Months | 4.45 | 15.4999 | 3.5022 | 5.93 | 564,265 | 2.54 | 57.08% |
6 Months | 18.35 | 20.00 | 3.5022 | 7.83 | 2,002,847 | -11.36 | -61.91% |
1 Year | 21.58 | 42.00 | 3.5022 | 10.92 | 2,183,554 | -14.59 | -67.61% |
3 Years | 60.50 | 167.50 | 3.5022 | 35.04 | 1,470,076 | -53.51 | -88.45% |
5 Years | 60.50 | 167.50 | 3.5022 | 35.04 | 1,470,076 | -53.51 | -88.45% |
Kintara Therapeutics Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America. |